SEC Form 4 · accession 0001104659-26-097406
Outlook Therapeutics, Inc. · OTLK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Charles Jahr
Officer — Chief Executive Officer · Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 14, 2026 · 8:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001649989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 14, 2026 | P$0 | 151,515 | — | A | 151,515 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants (right to buy)F2,F1 | $1.10 | Aug 14, 2026 | P | 151,515 | A | Aug 14, 2026 | Aug 14, 2031 | Common Stock | 151,515 | 151,515 | D |
Explanation of responses
- F1On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.
- F2The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031.